GlassScriptPhysician profile
Ryon K Nakasone
NPI 1114138351
$19,919.44
in general payments reported to CMS, 2019-2025
67 companies · $2,733 in 2025
The $2,733 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,311 · 2020: $950 · 2021: $2,457 · 2022: $3,185 · 2023: $3,908 · 2024: $3,376 · 2025: $2,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,618 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,618.14 |
| Education | $397.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,351.20 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Novartis Pharmaceuticals Corporation | $1,946.44 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,636.43 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $1,134.17 | 2019-2025 | Keytruda, Lynparza, Lenvima |
| Astellas Pharma US INC | $1,079.57 | 2019-2025 | Xtandi, Xospata, Padcev |
| Pfizer INC. | $1,029.64 | 2019-2025 | |
| Janssen Biotech, INC. | $885.38 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Genentech USA, INC. | $881.78 | 2019-2025 | Rozlytrek, Tecentriq, Alecensa |
| Incyte Corporation | $851.25 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $809.95 | 2019-2025 | Ninlaro, Fruzaqla, Advate |
| Amgen INC. | $605.56 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Eisai INC. | $557.30 | 2019-2025 | |
| US Oncology Corporate, INC. | $539.80 | 2023-2025 | |
| Genzyme Corporation | $481.18 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $426.68 | 2019-2025 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryon Nakasone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.